A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. - Wikidata - wikimedia - TriplyDB

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.

http://www.wikidata.org/entity/Q33265964

about

Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins The pancreas cancer microenvironment The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions.Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments.Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent.The soy-derived peptide Lunasin inhibits invasive potential of melanoma initiating cells Significance of talin in cancer progression and metastasis.Integrin αvβ3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy.Biological approaches to therapy of pancreatic cancer.Pancreatic cancer: molecular pathogenesis and new therapeutic targets.Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer Regional intra-arterial vs. systemic chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis of randomized controlled trials.An easily accessible sulfated saccharide mimetic inhibits in vitro human tumor cell adhesion and angiogenesis of vascular endothelial cells.A phase I study of continuous infusion cilengitide in patients with solid tumors.A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.Integrin targeted therapeutics.Differential growth inhibition of cerebral metastases by anti-angiogenic compounds Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.Current knowledge on pancreatic cancer.The Effect of Stromal Integrin β3-Deficiency on Two Different Tumors in Mice.The role of PET/CT in cervical cancer In vitro and in vivo drug disposition of cilengitide in animals and human.The differentiation of pancreatic tumor-initiating cells by vitronectin can be blocked by cilengitide Antagonizing Integrin β3 Increases Immunosuppression in Cancer.Combining molecular targeted agents with radiation therapy for malignant gliomas Integrins in angiogenesis and lymphangiogenesis Roles of integrins in tumor angiogenesis and lymphangiogenesis.Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer Integrin targeted drug and gene delivery.Jekyll and Hyde: the role of the microenvironment on the progression of cancer.Treatment options for advanced pancreatic cancer: a review.Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development Tumour but not stromal expression of β3 integrin is essential, and is required early, for spontaneous dissemination of bone-metastatic breast cancer.The effect of cilengitide in combination with irradiation and chemotherapy in head and neck squamous cell carcinoma cell lines.Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.Integrins as Therapeutic Targets: Successes and Cancers.Integrins in tumor angiogenesis and lymphangiogenesis.

P2860

Q24647759-10DA6B84-116F-40FD-BD68-21B6C599E0C5 Q26801806-98463C0E-26EE-46DF-AA1A-DB210349D6DF Q27026705-250B747E-E1CB-4158-B993-6E128204B8E9 Q28474747-619AFBCD-73E1-4F56-A570-29313C1239F1 Q30423854-EDCC7962-763C-4B2A-98FE-60B1DC00EB90 Q30483866-BE355972-2FF9-4A53-87F7-6616DCD6A1F2 Q33403498-0D937927-9D4B-4643-A169-097DADFEEAD0 Q33546368-BCB2C8B7-A9A0-4A27-AF5A-A3CB7E6A313A Q33648931-E09E0CCB-D41E-469B-8AA6-2CCC6CF0BB22 Q33763551-183F6EC3-91A5-460F-A928-C2A4750F77B0 Q33851309-7ADBF2AA-01D8-4F89-AC31-0FB5B1F121A6 Q33899938-86C45A33-424F-4014-86E3-CBC2218DCDDF Q33899954-EF7C39E8-CB78-4948-ACB7-B8B5DD21E4A6 Q34128953-0217F5F8-12D7-49A8-B6A6-B8E716817F34 Q34345296-7DEA87C6-D862-44E5-A3BF-5745920EACB1 Q34422665-72753763-DBE1-4C29-BE26-E14A02759323 Q34687225-09CC0295-FAE3-4066-BE39-6BFC4E863675 Q34818494-0E0D0176-4D7A-4B9E-9496-808B3777553C Q34912684-C36FAD86-203E-442E-B063-7552AD21E47B Q35304863-BA63F1A6-F87E-40E3-83D2-BCE9A7FCFAD5 Q35701298-379214E7-2710-46F5-918F-99BD29C83180 Q35971808-656A5E27-991A-4FB6-A39E-92AF2A129531 Q36507002-8F1EB729-50FC-4709-8B53-B5E47A93DDF0 Q36637204-AE37DDEC-B7AC-4C90-BF9C-D3B451001BA8 Q36719621-DB486D10-747A-48E8-9380-5C24093ACE6E Q36912649-ED27A10A-A919-417A-A686-57C711FF9983 Q37094368-A29C2275-14DC-4007-8C5D-AF64330D7F9D Q37099594-FCEB1D39-D9D1-4C8F-9444-18C71E6C5767 Q37170752-8A1912D4-F08F-49D6-8C1D-3EEE631810E4 Q37354204-92FEBAF3-E869-4586-ADD6-4105DF75720A Q37389574-2AA67A41-3E5C-4899-B864-7DDBB6B0D1EC Q37679945-BAA57A36-D4EA-47C6-885F-1CCC0947FE2E Q37815128-3C77BE90-D9AB-45D6-AE69-220DA1BCFC5B Q38062020-7B302871-1D20-43A8-B7D4-C8A603268DF3 Q38688235-4373008E-36E4-4287-9619-2430E0B23623 Q38937289-99276821-A43E-49A3-BD44-E8F963B6318B Q39021996-9C3BCB62-66F2-474C-9266-32969ED64AFD Q39770397-FA87561D-504E-440A-B297-00136516942A Q41670949-FBEB938A-B2DE-47D4-877B-58839E4571DB Q42263292-9B209E95-07D9-4587-852B-1145323DE399

P2860

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.

http://www.wikidata.org/entity/Q33265964

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

A randomized multi-center phas ...... nresectable pancreatic cancer.

@ast

A randomized multi-center phas ...... nresectable pancreatic cancer.

@en

type

label

A randomized multi-center phas ...... nresectable pancreatic cancer.

@ast

A randomized multi-center phas ...... nresectable pancreatic cancer.

@en

prefLabel

A randomized multi-center phas ...... nresectable pancreatic cancer.

@ast

A randomized multi-center phas ...... nresectable pancreatic cancer.

@en

P1433

Q33265964-12EA51C8-D1D0-44FB-8D1D-F6B232869C9B

P1476

Q33265964-8FCC613E-E13C-4316-9581-F49707E89802

P2093

Q33265964-097B5C8C-BEDE-4327-A257-FB1AFBE8BB25

Q33265964-0CFD8FA8-BFAB-4A35-A000-499B247F807D

Q33265964-0FE8BB2B-0BC2-4F0D-9B01-176BF7552FA9

Q33265964-18FDF43C-0623-4C26-8D55-8633CCC33C41

Q33265964-384767F8-80F2-4865-BD1D-626508E88F2C

Q33265964-41CDAD67-5471-43DD-8DA4-FBF5EA16EA0D

Q33265964-42A1074F-EFFF-4A53-89B9-433DFE15C6EC

Q33265964-4852CFB5-DC8A-4018-B02C-228E07314209

Q33265964-48D2531F-69AE-4669-BB1C-8C872D2477B0

Q33265964-51329D69-558E-4045-9A41-4DAA72828E7A

P2860

Q33265964-18AF3146-328F-4C49-B81E-86614FE131AC

Q33265964-1C9E6D21-32F1-4F75-96BA-80A05A7B6A47

Q33265964-230C8DB5-BB53-43FF-9540-E447622B4726

Q33265964-2DA2CDEE-72FE-46A5-9034-EA0B62905DD0

Q33265964-2DAA951D-0076-4DCE-A06E-C18015B027F7

Q33265964-3B6E2356-FFE1-4718-8715-BEE1FD3B7F3B

Q33265964-3EFD7F21-1F6F-4681-A388-E0254A32CAEA

Q33265964-429FABD2-C995-44E1-B89C-A72D2C970848

Q33265964-504AD8E7-4039-424E-B186-44F79EED391A

Q33265964-515CAFAB-BB3E-4214-B589-2C4E2AE0B822

P2888

Q33265964-7EA62B4C-C3EC-43B8-9F7A-8DF5D8522479

P304

Q33265964-F98FDAF6-A6F5-4115-A4C6-A059BE1B3D01

P31

Q33265964-C56BA093-9347-43CC-B017-B0435C022C70

P356

Q33265964-25C4A1D4-800D-48F5-A73D-C3FE15FF2D85

P407

Q33265964-ADF9BEC8-768B-4176-AFE1-64008FC2E24D

P478

Q33265964-3DE11FD9-5F8F-4D45-9E1D-923525D4E891

P50

Q33265964-6B220952-5BC6-427F-AABC-0AD8521D8BF5

Q33265964-E5FF0E4B-2A5F-4C49-8A3E-41AB28E8941B

P577

Q33265964-CD2AA6CE-98BA-4487-AC8D-7F5BE86BEABA

P5875

Q33265964-FD2F902C-0E09-487B-A4C5-5A7509024ABD

P6179

Q33265964-A96F87C4-CF8B-4C9C-9467-962298AC6565

P698

Q33265964-A539E2CA-8181-4BE2-AE57-C1ACA616DA0A

P921

Q33265964-15DD3B35-AEF8-405B-87D7-0C73FF62D434

P932

Q33265964-A37E12B9-0944-4906-B236-E769AA00AAD1

P356

1471-2407-6-285

P1433

P1476

A randomized multi-center phas ...... nresectable pancreatic cancer.

@en

P2093

Adrien A Tempia-Caliera

http://www.w3.org/2001/XMLSchema#string

Albert Abad Esteve

http://www.w3.org/2001/XMLSchema#string

Andreas Kovar

http://www.w3.org/2001/XMLSchema#string

Bart Neyns

http://www.w3.org/2001/XMLSchema#string

Christian Dittrich

http://www.w3.org/2001/XMLSchema#string

Daniel Castellano

http://www.w3.org/2001/XMLSchema#string

Dieter K Hossfeld

http://www.w3.org/2001/XMLSchema#string

Frank Dobrowolski

http://www.w3.org/2001/XMLSchema#string

Frieder Katz

http://www.w3.org/2001/XMLSchema#string

Helmut Oettle

http://www.w3.org/2001/XMLSchema#string

P2860

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Cancer statistics, 2005

Requirement of vascular integrin alpha v beta 3 for angiogenesis

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.

Integrin activation controls metastasis in human breast cancer

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.

Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents.

P2888

1471-2407-6-285

P304

285

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-6-285

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Marco Niedergethmann

P577

2006-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6643993

http://www.w3.org/2001/XMLSchema#string

P6179

1050531808

http://www.w3.org/2001/XMLSchema#string

P698

17156477

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

1764757

http://www.w3.org/2001/XMLSchema#string